U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07067567) titled 'A Study of AK146D1 for Injection in Advanced Solid Tumors' on June 18.
Brief Summary: This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.
Study Start Date: July 30
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: AK146D1 for injection
AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Akeso
Published by HT Digital Content Services with permission from Health Daily Dig...